Protein One is a development stage biotechnology company. The primary aim of the company is to deliver high quality purified, biologically active proteins to research labs, medical institutions and pharmaceutical companies via a Universal Protein Array (UPA) under development by the company to help companies with their drug discovery program.

In an effort to advance systems biology research, Protein One offers protein mutation or modification services which may very well enhance understanding of these protein alterations in mediating biological activities.

The purified proteins will be sold in two different formats: through the patent pending UPA system, or Individually by request. The company’s aim is to include over 300 purified active proteins in our inventory within two years, and to successfully transfer from a prototype to an operationally complete model of the UPA.

Protein One's expertise in active protein production allows us to provide customers with functionally active and highly purified recombinant proteins as well as native protein fractions from mammalian cells. Our product lines include general transcription factors, transcriptional activators and coactivators, pre-mRNA processing factors, tumor suppressors and other cancer related proteins.

Strategy & Focus

It is Protein One’s intent to maintain a leadership position in the proteomics industry by producing protein based Life Science Bioreagents. The purification of unique recombinant proteins, the creation of various protein array platforms and assay kits will enable scientists to further understand protein function and subsequently create new science applications and novel protein based drug discovery.

The scientific team continues to work towards the short term purification of a 500 recombinant protein catalog to include some complex, high market utility and very difficult to purify proteins many of which will only be available from Protein One. These diverse protein products associated with transcription, nuclear receptors, cancer and other diseases will form a basis for research use tools which will evolve into GMP products for clinical therapeutic and diagnostic utility in the near future.